Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Neurology

Journal Scan / Research · April 09, 2014

Oral Cladribine Delays Conversion to Clinically Definite Multiple Sclerosis at First Demyelinating Event

The Lancet Neurology

 

Additional Info

The Lancet Neurology
Effect of Oral Cladribine on Time to Conversion to Clinically Definite Multiple Sclerosis in Patients With a First Demyelinating Event (ORACLE MS): A Phase 3 Randomised Trial
Lancet Neurol 2014 Mar 01;13(3)257-267, TP Leist, G Comi, BA Cree, PK Coyle, MS Freedman, HP Hartung, P Vermersch, F Casset-Semanaz, M Scaramozza

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading